Autobahn Therapeutics
↗San Diego, USA
Autobahn Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of regenerative medicines for central nervous system (CNS) disorders. The company utilizes its proprietary brain-targeting chemistry platform to deliver small molecules across the blood-brain barrier with high precision, aiming to restore neurological function.
Their primary focus is on thyroid hormone receptor beta (TRβ) agonists, which play a critical role in remyelination and neuroprotection. By leveraging validated biology with a novel delivery approach, Autobahn seeks to address significant unmet needs in conditions like Multiple Sclerosis (MS) and Major Depressive Disorder (MDD).
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:N/A (Pre-revenue)
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$203M
Investors:Goldman Sachs Alternatives, Canaan Partners, ARCH Venture Partners, Cowen Healthcare Investments, Pfizer Ventures, Bristol Myers Squibb, Invus, Section 32
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 1b/2a
Modalities:Small molecule, Brain-targeting platform
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Pfizer (Investment/Strategic interest), Bristol Myers Squibb (Investment/Strategic interest)
COMPETITION
Position:Emerging
Competitors:Viking Therapeutics, Madrigal Pharmaceuticals, Contineum Therapeutics, Pipeline Therapeutics
LEADERSHIP
Key Executives:
Kevin Finney - CEO
Keith Wilcoxen - CSO
Gudarz Davar - CMO
Scientific Founders:Thomas Scanlan, Ph.D.
Board Members:Kevin Finney, Colin Walsh, Kristina Burow, Tim Anderson
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Autobahn Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.